Abstracts are open access.
Presentations (slides) and webcasts are reserved to ESMO Members and registered delegates.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The congress offered participants a glimpse into the future of anticancer therapies, focusing on promising new targets and agents with a particular emphasis on early drug development.
Speakers from both academia and industry participated in an expanded programme, including four new special sessions with industry addressing drug development, methodological, regulatory, strategic financing and investment issues, offering attendees a fresh, wide-ranging perspective on the development of innovative cancer therapeutics and their optimal implementation.
Abstracts are open access.
Presentations (slides) and webcasts are reserved to ESMO Members and registered delegates.
Create your own personalised agenda and browse the scientific programme by day, topic, cancer type and track with the ESMO events app.
The ESMO Daily Reporter is the official ESMO newspaper providing live reporting, highlights, critical insights on data presented at ESMO congresses, and expert opinions on controversial topics.
The ESMO TAT 2024 programme is online!
Please download your certificate from your ESMO area
The abstract submission for ESMO TAT 2024 is now closed!
Find here instructions to assist with your presentation
Find out more information about the sponsors of TAT 2024
Information about the Exhibition
Industry partners: find out how to get involved
The ESMO Targeted Anticancer Therapies 2024 (TAT) will take place at the Palais des Congrès in Paris, France
ESMO is committed to providing the best experience for attendees of ESMO TAT 2024
Information for media representatives
Find out more about the regulations to access the congress
Get in touch with the organisers of ESMO TAT 2024. You'll find the contact details here
Follow #ESMOTAT24 on Facebook, X (Twitter), LinkedIn, Instagram and YouTube
Frequently Asked Questions
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.